Synthetic metabolites of neurohypophyseal hormones. (Des-9-glycinamide)oxytocin and (des-9-glycinamide, des-8-leucine)oxytocin.

No abstract is available for this paper.

• Publication year

  1976

• Venue

  Journal of Medicinal Chemistry

• Publication date

  1976-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM00224A025PMID 1249815
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Solid-phase peptide synthesis.

  1996cited by this paper
• Neurohypophyseal hormones, analogs, and fragments: their effect on puromycin-induced amnesia.

  1975cited by this paper
• Melanocyte-stimulating hormone-release inhibiting hormone as a antidepressant. A pilot study.

  1974cited by this paper
• Influence of the tripeptide, PRO-ARG-GLY-(NH2), on ovulation induced with LH or synthetic LH-FSH releasing hormone in chlorpromazine-treated pro-oestrous rats.

  1973cited by this paper
• Deserpidine antagonism by a tripeptide, L-prolyl-L-leucyglycinamide.

  1973cited by this paper
• Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.

  1972cited by this paper
• Effect of corticotropin and desglycinamide 9 -lysine vasopressin on suppression of memory by puromycin.

  1972cited by this paper
• Release of pituitary melanocyte-stimulating hormone by the oxytocin fragment, H-Cys-Tyr-Ile-Gln-Asn-Oh.

  1971cited by this paper
• Regulation of formation and proposed structure of the factor inhibiting the release of melanocyte-stimulating hormone.

  1971cited by this paper
• Pituitary peptides. An octapeptide that stimulates conditioned avoidance acquisition in hypophysectomized rats.

  1971cited by this paper
• A solid-phase synthesis of (8-arginine)-vasopressin through a crystalline protected nonapeptide intermediate and biological properties of the hormone.

  1970cited by this paper
• Threshold and Receptor Reserve in the Action of Neurohypophyseal Peptides

  1970cited by this paper
• Partition Chromatography of Oxytocin on ‘Sephadex’

  1964cited by this paper
• A highly potent analogue of oxytocin, desamino-oxytocin.

  1962cited by this paper
• Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues.

  1960cited by this paper
• Differences in the antidiuretic responses of rats to the intravenous administration of lysine and arginine vasopressins.

  1958cited by this paper
• The effects of neurohypophysial extracts on the water transfer across the wall of the isolated urinary bladder of the toad Bufo marinus.

  1958cited by this paper
• Trail of sulfur research: from insulin to oxytocin.

  1956cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper
• A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract.

  1948cited by this paper

• Oxytocin Analogues for the Oral Treatment of Abdominal Pain.

  2024cites this paper
• Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin.

  2009cites this paper
• Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.

  2009cites this paper
• Design and synthesis of potent, highly selective vasopressin hypotensive agonists

  2006cites this paper
• Design of Oxytocin Antagonists, which are more Selective than Atosiban

  2001cites this paper
• Synthesis and structure–activity investigation of novel vasopressin hypotensive peptide agonists

  1999cites this paper
• Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.

  1995cites this paper
• Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors.

  1995cites this paper
• An exploration of the effects of L‐ and D‐tetrahydroisoquinoline‐3‐carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin

  1995cites this paper
• Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.

  1992cites this paper
• Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.

  1990cites this paper
• Penile erection and yawning induced by oxytocin and related peptides: structure-activity relationship.

  1989cites this paper
• Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.

  1989cites this paper
• 125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand.

  1988cites this paper
• Potent V2 vasopressin antagonists with structural changes at their C-terminals.

  1988cites this paper
• C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.

  1987cites this paper
• Synthesis of fragments of arginine vasopressin and oxytocin containing a cystine residue in position 6

  1984cites this paper
• Effects of Structural Changes on the Natriuretic Activity of Oxytocin Analogs in Conscious Rats 1

  1980cites this paper
• SYNTHETIC METABOLITES OF NEUROHYPOPHYSEAL HORMONES. (DES-9-GLYCINAMIDE)OXYTOCIN AND (DES-9-GLYCINAMIDE,DES-8-LEUCINE)OXYTOCIN

  1976cites this paper
• Importance of the third amino acid residue of oxytocin for its action on isolated rat uterus: study of relationship between hormone conformation and activity.

  1976cites this paper